Technical Analysis for MREO - Mereo BioPharma Group plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 3.17 | 7.09% | 0.21 |
MREO closed up 7.09 percent on Wednesday, May 15, 2024, on 56 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: May 21
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| 180 Bullish Setup | Bullish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 7.09% | |
| Down 3 Days in a Row | Weakness | 7.09% | |
| 50 DMA Resistance | Bearish | 6.73% | |
| Fell Below 50 DMA | Bearish | 4.62% | |
| 180 Bearish Setup | Bearish Swing Setup | 4.62% | |
| Outside Day | Range Expansion | 4.62% | |
| Upper Bollinger Band Touch | Strength | 4.62% | |
| Crossed Above 50 DMA | Bullish | -3.06% |
| Alert | Time |
|---|---|
| Up 5% | about 16 hours ago |
| Possible NR7 | about 17 hours ago |
| Rose Above 10 DMA | about 17 hours ago |
| 50 DMA Resistance | about 19 hours ago |
| Rose Above 50 DMA | about 19 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/21/2024
Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates that have substantial preclinical, clinical and manufacturing data packages. Mereo's four product candidates have previously generated positive clinical data for Mereo's target indications or in related indications. Mereo has commenced randomized Phase 2 clinical trials for all four of the product candidates. In connection with the merger with OncoMed, Mereo added two candidates to its pipeline, Navicixizumab and Etigilimab.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Rare Diseases Drug Discovery Clinical Research Clinical Trial Compugen
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Rare Diseases Drug Discovery Clinical Research Clinical Trial Compugen
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.36 |
| 52 Week Low | 0.9201 |
| Average Volume | 984,387 |
| 200-Day Moving Average | 2.42 |
| 50-Day Moving Average | 3.07 |
| 20-Day Moving Average | 2.96 |
| 10-Day Moving Average | 3.10 |
| Average True Range | 0.20 |
| RSI (14) | 55.16 |
| ADX | 17.56 |
| +DI | 23.24 |
| -DI | 17.00 |
| Chandelier Exit (Long, 3 ATRs) | 2.76 |
| Chandelier Exit (Short, 3 ATRs) | 3.12 |
| Upper Bollinger Bands | 3.34 |
| Lower Bollinger Band | 2.57 |
| Percent B (%b) | 0.78 |
| BandWidth | 26.14 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0229 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.45 | ||||
| Resistance 3 (R3) | 3.42 | 3.30 | 3.41 | ||
| Resistance 2 (R2) | 3.30 | 3.22 | 3.31 | 3.39 | |
| Resistance 1 (R1) | 3.23 | 3.18 | 3.26 | 3.26 | 3.37 |
| Pivot Point | 3.11 | 3.11 | 3.12 | 3.12 | 3.11 |
| Support 1 (S1) | 3.04 | 3.03 | 3.08 | 3.08 | 2.97 |
| Support 2 (S2) | 2.92 | 2.99 | 2.93 | 2.95 | |
| Support 3 (S3) | 2.85 | 2.92 | 2.93 | ||
| Support 4 (S4) | 2.89 |
